

hossam maghraby




بسم الله الرحمن الرحيم



hossam maghraby



شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم



hossam maghraby



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



hossam maghraby



شبكة المعلومات الجامعية




بعض الوثائق الأصلية تالفة



hossam maghraby



بالرسالة صفحات
لم ترد بالأصل



ACUTE STROKE MANAGEMENT

B15A19

Thesis

Submitted in partial fulfillment for the requirements of
M.D. in Neurology

By

Osama Eid El-Deib

M.B.B.Ch.

M.Sc. Neuropsychiatry

Assistant Lecturer In Neurology

Al-Monofiya University

Under the Supervision

Prof. Dr. Fathi Mahmoud Afifi

Prof. of Neurology, Faculty of Medicine, Al-Azhar University

Prof. Dr. Mohamed El-Bahay Reda

Prof. of Neurology, Faculty of Medicine, Al-Azhar University



Prof. Dr. Mohamed Saeid Abdel-Baki

Prof. of Neurology and Chairman of Neurology Department,
Faculty of Medicine, Al-Monofiya University

Faculty of Medicine

Al-Azhar University

2000



قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا
عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

كَتَبَ اللَّهُ الْقُدُّوسُ
الْبَرُّ - ٢٢ -

ACKNOWLEDGMENT

I always feel indebted to **Allah** whose blessings on me can not be counted.

I express my sincere and deepest gratitude to **Prof. Dr. Fathi Mahmoud Afifi**, Prof. of Neurology, Faculty of Medicine, Al-Azhar University, for constant supervision, fruitful discussion, continuous interest and efforts for reading the manuscript.

I am also very much grateful to **Prof. Dr. Mohamed El-Bahay Reda**, Prof. of Neurology, Faculty of Medicine, Al-Azhar University, for his kind supervision, fruitful discussion continuous guidance and efforts for reading the manuscript.

I am also indebted to **Prof. Dr. Mohamed Said Abdel-Baki**, Prof. of Neurology and Chairman of Neurology Department, Faculty of Medicine, Al-Monofiya University, for his kind help throughout the progress of the work.

I would like to express my sincere deepest gratitude to **Prof. Dr. Abdel-Latif Moussa Osman**, Prof. of Neurology, Chairman of Neurology Department, Faculty of Medicine, Al-Azhar University, for suggesting the points of research, facilitating all difficulties for the clinical work, stimulating discussion and encouragement during development of the work.

I express my sincere thanks to all staff members, colleagues and nursing staff in Neurology Department in Al-Azhar and Al-Monofiya Universities and Naser Institute Hospital, especially **Ass. Prof. Dr. Mohamed Elwan**, **Ass. Prof. Dr. Nabil Hussein**, **Lecturer Dr. Tarek Minisi**, **Lecturer Dr. Mohamed Okda**, who helped me directly or indirectly throughout the progress of the work.

I am also indebted to our patients who helped me throughout the progress of this work.

Finally, I would like to extend my gratitude to my **family**, for their currently advice and continuous encouragement and to whom I dedicate this work.

CONTENTS

<i>Subject</i>	<i>Page</i>
List of Tables.	
List of Figures.	
List of Abbreviations.	
CHAPTER I.	
Introduction.	1
Aim of the work.	3
CHAPTER II. Review of Literature	
1- Pathophysiology.	4
1-1- Epidemiology of stroke.	4
1-2- Normal and critical limits of cerebral blood flow.	5
1-3- Ischemic pnumbra.	6
1-4- Pathogenesis of ischemic stroke.	8
1-5- Vulnerability of the different neuronal tissues.	11
1-6- Improvement of ischemic stroke.	14
1-7- Fibrinolytic system.	15
2- Medical therapies of ischemic stroke.	19
2-1- Fibrinolytics.	22
2-1-1- Tissue plasminogen activator.	22
2-1-2- Streptokinase.	23
2-1-3- Urokinase.	24
2-1-4- Seruplase.	25
2-1-5- Thrombolysis for myocardial infarction.	25
2-1-6- Animal studies.	26
2-1-7- Clinical studies.	28
2-1-8- Arterial recanalization.	31
2-1-9- Complications.	40
2-1-10- Time and thrombolytic therapy.	46

<i>Subject</i>	<i>Page</i>
2-1-11- Combined therapy.	47
2-1-12- Thrombolytic therapy for dural sinus thrombosis.	49
2-1-13- Thrombolytic therapy for subarachnoid hemorrhage.	49
2-1-14- Thrombolytic therapy for intracerebral hemorrhage.	50
2-2- Neuroprotective.	51
2-2-1- Glutamate and neuronal damage.	51
2-2-2- Neuroprotection and NMDA receptor.	53
2-2-3- Neuroprotective agents.	53
2-3- Anticoagulants.	57
2-3-1- Heparin.	57
2-3-2- Oral anticoagulant.	63
2-3-3- Platelet antiaggrigants.	64
CHAPTER III. Subjects and Methods.	68
CHAPTER IV. Results.	79
CHAPTER V. Discussion.	95
1- Outcome improvement.	96
2- Complications.	98
2-1- Intracerebral hemorrhage.	98
2-2- Reocclusion.	100
2-3- Other complications.	101
3- Type of thrombolytics.	101
4- Time window.	102
5- Dosage.	104
6- Quality of life and health care.	104
CHAPTER VI. Summary, Conclusions and Recommendations.	106
REFERENCES.	111
Arabic Summary.	

LIST OF TABLES

<i>Table</i>	<i>Page</i>
1. Summary of major randomized clinical trials of intravenous thrombolytic therapy for stroke that have been completed.	38
2. Contraindications for Heparinization.	60
3. National Institute of Health Stroke Scale (NIHSS).	72
4. Characteristics of the 18 thrombolytically treated patients with t-PA (G I).	83
5. Characteristics of the 15 patients treated with low molecular weight heparin (G II).	85
6. Comparison between G I and G II, Age, NIHSS and delay in treatment.	87
7. Comparison between G I & G II as regrads improvement, No and %.	88
8. Comparison between improved and non-improved cases in G I, Age, NIH and delay in treatment.	89

LIST OF FIGURES

<i>Figure</i>	<i>Page</i>
1. Schematic representation of the fibrinolytic system.	16
2. Mechanisms of neuronal death during focal brain ischemia. . . .	51
3. Axial CT scan for P ₅ , who suffered from brain stem manifestation 24 hours after t-PA treatment, without apparent lesion.	90
4. A T ₂ -weighted MRI taken from P ₅ , 7 days after t-PA treatment, shows Rt thalamic infarction.	90
5. Axial CT scan for P ₆ before t-PA treatment, without apparent lesion.	91
6. Axial CT scan for P ₆ 24 hours after t-PA treatment shows cerebral hemorrhage.	91
7. Axial CT scan for P ₁₁ before t-PA treatment, without apparent lesion.	92
8. Axial CT scan for P ₁₁ , 24 hours after t-PA treatment, shows cerebral hemorrhage.	92
9. Axial CT scan for P ₁₁ , before low molecular weight heparin treatment, without apparent lesion.	93
10. Axial CT scan for P ₁₁ , 3 days after starting low molecular weight heparin treatment, shows cerebral hemorrhage.	93
11. Axial CT scan for P ₁₆ , before t-PA treatment, without apparent lesion.	94
12. Axial CT scan for P ₁₆ , 7 days after t-PA treatment, shows H small parietal infarction.	94

LIST OF ABBREVIATIONS

AF	Atrial fibrillation.
BBB	Blood brain barrier.
Ca	Calcium.
CBF	Cerebral blood flow.
CT	Computed tomography.
DVT	Deep vein thrombosis.
F	Female.
Gp	Glyco protein.
ICH	Intracerebral hemorrhage.
K	Potassium.
Lt	Left.
M	Male.
MCA	Middle cerebral artery.
MRI	Magnetic resonance imaging.
Na	Sodium.
NIHSS	National Institute of Health Stroke Scale.
NINDS	National Institute of Neurological Disorders and Stroke.
NMDA	N-methyl-D-aspartate.
No	Number.
PCA	Posterior cerebral artery.
PT	Prothrombin time.
PTT	Partial thromboplastin time.
rCMRglu	regional Cerebral metabolic rate of glucose.
rCMRO ₂	regional Cerebral metabolic rate of oxygen.
RIND	Reversible ischemic neurologic deficit.
SPECT	Single photon emission tomography.
TAP	Tandem arterial pathology.
TCD	Trancranial doppler.
TIA	Transient ischemic attack.
t-PA	tissue plasminogen activator.
ttt	treatment.

CHAPTER I

INTRODUCTION

CHAPTER I

INTRODUCTION

Many treatments for acute stroke have been devised, but no treatment has yet been conclusively shown to reduce early mortality or disability (Counsell & Sandercock, 1994).

As a result, no clear consensus exists about the appropriate hospital treatment for patients with acute ischemic stroke and substantial variation exists both within and between different countries in the management of stroke (Ricci, 1995).

Such wide variation in practice reflect, at least in part, the lack of generally convincing evidence about the balance of benefit and risk of many treatments (Chen, 1996).

It has to be stressed that the time lag from onset to treatment is the crucial denominator for therapeutic success. Attempts to apply treatment as early as possible requires immediate reliable diagnosis for cerebral ischemia in presumed patients (Kriegen & Hocke, 1996).

Computed tomography scanning is still the most widely used tool in clinical centers hospitalizing stroke patients, and it is unlikely to be routinely replaced by other imaging devices in the next years. This stresses the urgent need both for reaching for a general consensus on the criteria for identification of early CT signs and for the widest possible diffusion of this expertise (Toni, 1996). However, ultrafast diffusion/perfusion MRI can